Literature DB >> 21508125

Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.

Katherine R Calvo1, Donald C Vinh, Irina Maric, Weixin Wang, Pierre Noel, Maryalice Stetler-Stevenson, Diane C Arthur, Mark Raffeld, Amalia Dutra, Evgenia Pak, Kyungjae Myung, Amy P Hsu, Dennis D Hickstein, Stefania Pittaluga, Steven M Holland.   

Abstract

A novel, genetic immunodeficiency syndrome has been recently described, herein termed "MonoMAC". It is characterized by severe circulating monocytopenia, NK- and B-lymphocytopenia, severe infections with M. avium complex (MAC), and risk of progression to myelodysplasia/acute myelogenous leukemia. Detailed bone marrow analyses performed on 18 patients further define this disorder. The majority of patients had hypocellular marrows with reticulin fibrosis and multilineage dysplasia affecting the myeloid (72%), erythroid (83%) and megakaryocytic (100%) lineages. Cytogenetic abnormalities were present in 10 of 17 (59%). Despite B-lymphocytopenia, plasma cells were present but were abnormal (e.g. CD56(+)) in nearly half of cases. Increased T-cell large granular lymphocyte populations were present in 28% of patients. Chromosomal breakage studies, cell cycle checkpoint functions, and sequencing of TERT and K-RAS genes revealed no abnormalities. MonoMAC appears to be a unique, inherited syndrome of bone marrow failure. We describe distinctive bone marrow features to help in its recognition and diagnosis. (Clinicaltrials.gov identifiers: NCT00018044, NCT00923364, NCT01212055).

Entities:  

Mesh:

Year:  2011        PMID: 21508125      PMCID: PMC3148917          DOI: 10.3324/haematol.2011.041152

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  19 in total

1.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

2.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

3.  Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity.

Authors:  G Lambertenghi-Deliliers; A Orazi; R Luksch; C Annaloro; D Soligo
Journal:  Br J Haematol       Date:  1991-06       Impact factor: 6.998

4.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

5.  Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Authors:  M Ocqueteau; A Orfao; J Almeida; J Bladé; M González; R García-Sanz; C López-Berges; M J Moro; J Hernández; L Escribano; D Caballero; M Rozman; J F San Miguel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

6.  Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes.

Authors:  G Buesche; H Teoman; W Wilczak; A Ganser; H Hecker; L Wilkens; G Göhring; B Schlegelberger; O Bock; A Georgii; H Kreipe
Journal:  Leukemia       Date:  2007-11-22       Impact factor: 11.528

7.  Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.

Authors:  Jing Zhang; Jing Wang; Yangang Liu; Harwin Sidik; Ken H Young; Harvey F Lodish; Mark D Fleming
Journal:  Blood       Date:  2008-12-09       Impact factor: 22.113

8.  The reticulin content of bone marrow in acute leukaemia in adults.

Authors:  A Manoharan; R Horsley; W R Pitney
Journal:  Br J Haematol       Date:  1979-10       Impact factor: 6.998

9.  Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.

Authors:  Maria G Ioannou; Efstathios Stathakis; Andreas C Lazaris; Thomas Papathomas; Evangelos Tsiambas; George K Koukoulis
Journal:  Pathol Oncol Res       Date:  2008-06-14       Impact factor: 3.201

10.  Myelodysplastic syndromes: incidence and survival in the United States.

Authors:  Xiaomei Ma; Monique Does; Azra Raza; Susan T Mayne
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

View more
  48 in total

Review 1.  GATA2 deficiency.

Authors:  Amy P Hsu; Lisa J McReynolds; Steven M Holland
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-02

2.  MonoMAC versus idiopathic CD4+ lymphocytopenia. Comment to Haematologica. 2011;96(8):1221-5.

Authors:  Vicki H Chu; Jonathan L Curry; M Tarek Elghetany; Choladda V Curry
Journal:  Haematologica       Date:  2012-04       Impact factor: 9.941

3.  GATA2 mutations lead to MDS and AML.

Authors:  R Katherine Hyde; P Paul Liu
Journal:  Nat Genet       Date:  2011-09-28       Impact factor: 38.330

4.  Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Authors:  Daria V Babushok; Monica Bessler; Timothy S Olson
Journal:  Leuk Lymphoma       Date:  2015-12-23

Review 5.  MonoMAC syndrome in a patient with a GATA2 mutation: case report and review of the literature.

Authors:  Jose F Camargo; Stephen A Lobo; Amy P Hsu; Christa S Zerbe; Gary P Wormser; Steven M Holland
Journal:  Clin Infect Dis       Date:  2013-05-31       Impact factor: 9.079

6.  Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.

Authors:  Jennifer Cuellar-Rodriguez; Juan Gea-Banacloche; Alexandra F Freeman; Amy P Hsu; Christa S Zerbe; Katherine R Calvo; Jennifer Wilder; Roger Kurlander; Kenneth N Olivier; Steven M Holland; Dennis D Hickstein
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

7.  MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

Authors:  Lisa J McReynolds; Yanqin Yang; Hong Yuen Wong; Jingrong Tang; Yubo Zhang; Matthew P Mulé; Janine Daub; Cindy Palmer; Ladan Foruraghi; Qingguo Liu; Jun Zhu; Weixin Wang; Robert R West; Marielle E Yohe; Amy P Hsu; Dennis D Hickstein; Danielle M Townsley; Steven M Holland; Katherine R Calvo; Christopher S Hourigan
Journal:  Leuk Res       Date:  2018-12-04       Impact factor: 3.156

8.  Dendritic cell, monocyte, B and NK lymphoid deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic syndrome.

Authors:  Venetia Bigley; Matthew Collin
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

Review 9.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

Review 10.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.